Some adverse effects of cytarabine in leukemic rats | ||||
| Benha Veterinary Medical Journal | ||||
| Article 22, Volume 31, Issue 2, December 2016, Page 165-170 PDF (296.47 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bvmj.2016.31286 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| M. G. Elsayed1; Enas A.H. Farag2; Hanan S. Khaled3 | ||||
| 1Department of pharmacology, Faculty of Veterinary Medicine, Benha University | ||||
| 2Animal health research institute Benha branch | ||||
| 3pharmaceutical company | ||||
| Abstract | ||||
| In the present work, the biochemical and hematological parameters as well as histological changes following intravenous injection of 2 mg/ kg for 7 days and 3 mg cytarabine for 5 days in both normal and leukemic rats were studied. Sample were taken in the first, second and third week after end of administration of cytarabine. Both normal and leukemic rats showed significant increase in serum total bilirubin, AST, ALT, ALP, total protein and albumin after intravenous administration of cytarabine either 2 mg/kg body weight for 7 days or 3 mg/kg body weight for 5 days. The effect of intravenous injection of cytarabine either 2 mg/kg body weight for 7 days or 3 mg/kg body weight for 5 days on serum creatinine level in normal and leukemic rats showed a significant changes of kidney function through estimation of serum creatinine, urea and creatine kinase level. Intravenous injection of cytarabine either 2 mg/kg body weight for 7 days or 3 mg /kg body weight for 5 days induce significant increase on lipid profile (cholesterol and triglyceride) and MDA concentration in normal and leukemic rats | ||||
| Keywords | ||||
| cytarabine; Lipid profile; leukemic rats; MDA | ||||
|
Statistics Article View: 112 PDF Download: 514 |
||||
